Clinical applications of B-type natriuretic peptides

Trends in Endocrinology and Metabolism

Volumn 15, Issue 4, 2004, Pages 170-174

  Richards, A Mark ^a   Lainchbury, John G ^a   Troughton, Richard W ^a   Espiner, Eric A ^a   Nicholls, M Gary ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOBUTAMINE; NESERITIDE; NESIRITIDE; NEUROHORMONE; RECOMBINANT PROTEIN;

ACUTE HEART FAILURE; BLOOD LEVEL; CLINICAL TRIAL; DIURETIC ACTIVITY; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE PRESSURE; HUMAN; HYPOTENSION; KIDNEY FUNCTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; SCREENING; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; MASS SCREENING; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS;

EID: 1942518220     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2004.03.005     Document Type: Review

References (50)

1. Burnett J.C. Jr, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 231:1986;1145-1147.
2. Raine A.E.G., et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N. Engl. J. Med. 315:1986;533-537.
3. Richards A.M., et al. Plasma α natriuretic peptide in cardiac impairment. BMJ. 293:1986;409-412.
4. Richards A.M., et al. Brain natriuretic factor: regional plasma concentrations and inter-relations with haemodynamic status in cardiac disease. Br. Heart J. 69:1993;414-417.
5. Yasue H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203.
6. Mukoyama M., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. 87:1991;1402-1412.
7. Sumida H., et al. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J. Am. Coll. Cardiol. 25:1995;1105-1110.
8. Nakamura S., et al. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am. J. Hypertens. 4:1991;909-912.
9. Pucci A., et al. Localization of brain and atrial natriuretic peptide in human and porcine heart. Int. J. Cardiol. 34:1992;237-247.
10. Leskinen H., et al. Combined inhibition of endothelin and angiotensin II receptors blocks volume load-induced cardiac hormone release. Circ. Res. 80:1997;114-123.
11. Skvorak J.P., et al. Endothelin acts as a paracrine regulator of stretch-induced atrial natriuretic peptide release. Am. J. Physiol. 269:1995;R1093-R1098.
12. Lee M.E., et al. Role of endogenous atrial natriuretic factor in acute congestive heart failure. J. Clin. Invest. 84:1989;1962-1966.
13. Wada A., et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation. 89:1994;2232-2240.
14. Oliver P.M., et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc. Natl. Acad. Sci. U. S. A. 94:1997;14730-14735.
15. Tamura N., et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4239-4244.
16. Richards A.M., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 97:1998;1921-1929.
17. Davis M., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 343:1994;440-444.
18. Cowie M.R., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:1997;1349-1353.
19. Dao Q., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol. 37:2001;379-385.
20. Maisel A.S., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347:2002;161-167.
21. Lainchbury J.G., et al. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J. Am. Coll. Cardiol. 42:2003;728-735.
22. Wright S.P., et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care. A randomized, controlled trial. J. Am. Coll. Cardiol. 42:2003;1793-1800.
23. McDonagh T.A., et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 350:1997;829-833.
24. McDonagh T.A., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 351:1998;9-13.
25. Davis K.M., et al. Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. J.A.M.A. 267:1992;2625-2629.
26. Swedberg K., et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 82:1990;1730-1736.
27. Vantrimpont R., et al. Additive beneficial effects of β-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study. J. Am. Coll. Cardiol. 29:1997;229-236.
28. Richards A.M., et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation. 99:1999;786-792.
29. Cheng V., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J. Am. Coll. Cardiol. 37:2001;386-391.
30. Koglin J., et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J. Am. Coll. Cardiol. 38:2001;1934-1941.
31. Richards A.M., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 37:2001;1781-1787.
32. Anand I.S., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation. 107:2003;1278-1283.
33. Omland T., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 93:1996;1963-1969.
34. Arakawa N., et al. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J. Am. Coll. Cardiol. 27:1996;1656-1661.
35. De Lemos J.A., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345:2001;1014-1021.
36. Jernberg T., et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J. Am. Coll. Cardiol. 40:2002;437-445.
37. Omland T., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 106:2002;2913-2918.
38. Richards A.M., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 107:2003;2786-2792.
39. Murdoch D.R., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am. Heart J. 138:1999;1126-1132.
40. Troughton R.W., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:2000;1126-1130.
41. Holmes S.J., et al. Renal, endocrine and hemodynamic effects of human brain natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 76:1993;91-96.
42. Richards A.M., et al. Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension. J. Hypertens. 11:1993;163-170.
43. Hunt P.J., et al. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J. Clin. Endocrinol. Metab. 81:1996;3871-3876.
44. Lainchbury J.G., et al. The effect of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension. 30:1997;398-404.
45. Lainchbury J.G., et al. Bioactivity and interactions of adrenomedullin and brain natriuretic peptide in patients with heart failure. Hypertension. 34:1999;70-75.
46. Yoshimura M., et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 84:1991;1581-1588.
47. Mills R.M., et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure. A randomized, double-blind, placebo-controlled clinical trial. J. Am. Coll. Cardiol. 34:1999;155-162.
48. Colucci W.S., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med. 343:2000;246-253.
49. Silver M.A., et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J. Am. Coll. Cardiol. 39:2002;798-803.
50. Sudoh T., et al. A new natriuretic peptide in porcine brain. Nature. 332:1988;78-81.